Some strains of tuberculosis (TB) are resistant to several different drugs. Multidrug-resistant TB (MDR-TB) can usually be treated successfully after identifying which drugs the bacteria are still susceptible to. A strain of TB that is resistant to a larger number of drugs is known as extensively drug-resistant TB (XDR-TB).

Drug-resistant TB: latest news

Drug-resistant TB features

Drug-resistant TB news from aidsmap

More news

Drug-resistant TB news selected from other sources

  • 49th Union World Conference on Lung Health: 90 percent of participants in short-course XDR-TB regimen cured after six months

    New results from the ongoing Nix-TB trial continue to confirm a short-course treatment regimen of bedaquiline – one of the two newest drugs to treat TB in half a century – linezolid and pretomanid offers a significantly improved treatment option for people infected with drug resistant forms of tuberculosis, researchers said here.

    05 November 2018 | Science Speaks
  • Bedaquiline price protests hit World Lung Conference launch

    As the opening ceremony of the 49th Union World Conference on Lung Health kicked off in the Netherlands last night, protesting activists demanded Johnson & Johnson (J&J) slash its price for the blockbuster tuberculosis (TB) drug, bedaquiline.

    26 October 2018 | Health-e
  • Johnson & Johnson prices keep key TB medicines out of reach

    As US pharmaceutical corporation Johnson & Johnson (J&J) continues to charge high prices for its newer tuberculosis (TB) drug bedaquiline, people with drug-resistant tuberculosis (DR-TB) are forced to go without the best possible treatments, according to a new report—DR-TB Drugs Under the Microscope—released today by Doctors Without Borders/Médecins Sans Frontières (MSF) at the 49th Union World Conference on Lung Health in The Hague. J&J should cut the price of bedaquiline in half so more lives can be saved, said the international medical humanitarian organization MSF.

    23 October 2018 | MSF
  • DR-TB Drugs Under the Microscope, 5th Edition

    The 5th edition of “DR-TB Drugs Under the Microscope” chronicles the changing landscape of available treatments for DR-TB, outlines the key barriers to accessing the most effective treatments, and makes recommendations for action that can improve TB care on a global scale.

    23 October 2018 | MSF
  • Scientists warn of global crisis over failure to tackle tuberculosis

    Heads of state, doctors and scientists will gather in New York next week to discuss one of the world’s most alarming medical crises: the failure of global efforts to tackle tuberculosis, the deadliest infectious disease on Earth.

    18 September 2018 | The Guardian
  • SimpliciTB Clinical Trial Launched with First Patients in Tbilisi, Georgia

    New pivotal trial examines potential of BPaMZ regimen to shorten treatment for tuberculosis and multidrug-resistant tuberculosis.

    28 August 2018 | TB Alliance
  • How smartphones are becoming a weapon in the global fight against tuberculosis

    Mobile technologies devised by researchers at the University of California, San Diego, and Johns Hopkins are allowing patients to use their phones to record daily medication intake. The encrypted videos are sent to public health workers who can watch them from their cubicles, instead of traveling long distances every day to visit patients at their homes or workplaces.

    21 August 2018 | STAT
  • WHO announces landmark changes in MDR-TB treatment regimens

    Major improvement in treatment outcomes and quality of life of patients with multidrug-resistant tuberculosis (MDR-TB) are expected, following key changes in MDR-TB treatment announced by WHO today.

    20 August 2018 | World Health Organization
  • MSF applauds World Health Organization's recommendation of improved tuberculosis treatment options

    Médecins Sans Frontières (MSF) today welcomed the new World Health Organization (WHO) recommendations for improved treatment for people with drug-resistant tuberculosis (DR-TB), prioritising the use of several oral drugs, including the newer drug bedaquiline, and minimising the use of drugs that must be injected.

    20 August 2018 | ReliefWeb
  • All-access for blockbuster TB drug in South Africa

    The country made history on Monday when the health department announced that all drug-resistant tuberculosis (DR-TB) patients will be eligible to receive the new medicine, bedaquiline. “The Department of Health’s [DoH] commitment on bedaquiline is momentous globally and marks a new era of DR-TB management where we are really prioritising the patient,” Doctors Without Borders’ Dr Anja Reuters told Health-e News.

    19 June 2018 | Health-e
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.

See also

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.